PHARMARON(SZ:300759)2024-10-31 05:52Financial Performance - In Q3 2024, the company achieved a revenue of RMB 3,213 million, reflecting a 10.0% year-over-year (YoY) growth and a 9.5% quarter-over-quarter (QoQ) increase [7] - The net profit attributable to shareholders was RMB 308 million, down 12.6% YoY and significantly down 65.1% QoQ [7] - Non-IFRS adjusted net profit for Q3 2024 was RMB 417 million, up 18.7% QoQ but down 13.2% YoY [7] Year-to-Date Performance - For the first three quarters of 2024, total revenue reached RMB 8,817 million, a 3.0% increase YoY [9] - Net profit attributable to shareholders for 1-3Q 2024 was RMB 1,422 million, up 24.8% YoY [9] - Non-IFRS adjusted net profit for the same period was RMB 1,107 million, down 21.6% YoY [9] Revenue Composition - Revenue breakdown for 1-3Q 2024: - Laboratory services: 59% - Small molecule CDMO: 22% - Clinical research services: 15% - Large molecule and CGT services: 4% [10] - Revenue from domestic delivery increased by 3.7%, while overseas delivery decreased by 1.3% [10] Client Revenue Growth - Revenue from North American clients grew by 4.3%, while European clients saw a 15.7% increase [11] - Revenue from Chinese clients declined by 12.1% [11] - Revenue from the top 20 pharmaceutical companies increased by 3.4% [11] Cost and Expenses - Selling and distribution expenses accounted for 11.3% of revenue in 1-3Q 2024 [21] - Administrative expenses represented 13.4% of revenue during the same period [21] - Research and development expenses were 3.8% of revenue in 1-3Q 2024 [22] Future Outlook - The company anticipates a revenue growth of over 10% in the second half of 2024 [29] - The pharmaceutical and healthcare industry is expected to continue its development despite temporary market pressures [29] - The company aims to enhance efficiency and reduce costs through an integrated and international development strategy [29]